CNS Pharmaceuticals (CNSP) Reiterates Operational Progress and Addresses Recent Share Price Activity
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/19/2026
- S&P 500, Nasdaq set to open higher as AI stocks rebound ahead of earnings rush
- U.S. economy is "booming," JPMorgan’s Dimon says
- Musk pledges one share of SpaceX to every U.S. child
- Oil slips from five-month high with Hormuz transits in focus
- Prepare to buy the dip as U.S. stock selloff nears its end: Morgan Stanley
- Brazil's Bolsonaro, Lula spar in first debate as personal attacks fly
- S&P 500, Nasdaq set to open higher as AI stocks rebound ahead of earnings rush
- Microsoft pulls out of UK data center deal with Nscale, Telegraph reports
- AST SpaceMobile partners with four European operators on MSS spectrum
- Lithuanians forced to take shelter after suspected drone enters airspace
CNS Pharmaceuticals Reiterates Operational Progress and Addresses Recent Share Price Activity in Video to Shareholders
March 9, 2022 9:20 AM ESTHOUSTON, March 9, 2022 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today released a video to shareholders reiterating its operational and clinical progress for lead product candidate,... More



